Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NVG-291

Peptide · developed by NervGen Pharma

Phase 3 Most advanced trial

NGEN Developer

1 Registered trials

What is NVG-291?

NVG-291 is a peptide therapeutic administered by subcutaneous injection designed to promote nervous system repair and functional recovery following chronic spinal cord injury.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Peptide
Therapy area: Neurology
Developer: NervGen Pharma (NGEN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07799532	Phase 3	Chronic Spinal Cord Injury	Recruiting	NGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Spinal Cord Injury

Sources

ClinicalTrials.gov NCT07799532

Updated Oct 3, 2026. Something wrong or missing? Report it on the NGEN page.

Follow NGEN, the company behind NVG-291

See NGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NGEN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z